Stockscreener 앱 받기
5.78
3.03%
0.17
시간 외 거래:
5.84
0.06
+1.04%
Iovance Biotherapeutics Inc 주식(IOVA)의 최신 뉴스
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Iovance Biotherapeutics (IOVA) to Release Quarterly Earnings on Wednesday - MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Sold by Rice Hall James & Associates LLC - MarketBeat
Will Iovance Biotherapeutics (IOVA) Report Negative Earnings Next Week? What You Should Know - Nasdaq
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Iovance Biotherapeutics, Inc. (IOVA) - ACCESS Newswire
My 3 Favorite Stocks to Buy Right Now - The Motley Fool
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) - MSN
Iovance Biotherapeutics to Report Fourth Quarter and Full - GlobeNewswire
Biotech Spotlight: Iovance's Crucial Year-End Results & TIL Therapy Updates Coming Feb 27 - StockTitan
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 7.3%Time to Buy? - MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Purchased by Banque Pictet & Cie SA - MarketBeat
Iovance Biotherapeutics (NASDAQ:IOVA) Hits New 1-Year LowShould You Sell? - MarketBeat
Executive Compensation Alert: Iovance's Strategic Move with 305K Share Package for Commercial Chief - StockTitan
Stifel maintains Buy on Iovance Biotherapeutics, target at $21 - MSN
Why Iovance Biotherapeutics Stock Zoomed More Than 5% Higher Today - AOL
(IOVA) Trading Report - Stock Traders Daily
Iovance Biotherapeutics appoints new chief commercial officer - MSN
Jennison Associates LLC Buys Shares of 66,568 Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
Lion Biotechnologies Submits Investigational New Drug Application to Conduct Phase 2 Study in Metastatic Melanoma - Marketscreener.com
Iovance Biotherapeutics Shares Fell Today: What's Going On? - Benzinga
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024 - br.ADVFN.com
Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer - GlobeNewswire
Iovance Lands Former Celgene & BMS Executive to Accelerate TIL Therapy Commercialization | $IOVA - StockTitan
What's Going On With Iovance Biotherapeutics Today? - MSN
Iovance Biotherapeutics (NASDAQ:IOVA) Hits New 12-Month Low on Analyst Downgrade - MarketBeat
Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 12-Month Low on Analyst Downgrade - MarketBeat
SG Americas Securities LLC Purchases Shares of 69,625 Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
Iovance Biotherapeutics (NASDAQ:IOVA) Price Target Lowered to $7.50 at Piper Sandler - MarketBeat
Oversold Conditions For Iovance Biotherapeutics (IOVA) - Nasdaq
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives $23.00 Consensus Target Price from Analysts - MarketBeat
What's Wrong With Iovance Biotherapeutics Stock? - MSN
Institutional owners may consider drastic measures as Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) recent US$122m drop adds to long-term losses - Simply Wall St
(IOVA) Investment Report - Stock Traders Daily
Lion Biotechnologies, Inc. Appoints Michael T. Lotze, MD, as Chief Scientific Officer and Vice President of Research and Development - Marketscreener.com
Stifel maintains Buy on Iovance stock with $21 target - MSN
Where Will Iovance Biotherapeutics Be in 5 Years? - MSN
Iovance Biotherapeutics, Inc. (IOVA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Iovance Biotherapeutics (IOVA) Forecasts Strong Growth Due to Flagship Treatment - TipRanks
0.27%
3.05%
자본화:
|
볼륨(24시간):